Trials | Follow-up time (days post-therapy) | ||||||||
---|---|---|---|---|---|---|---|---|---|
0 | 7 | 30 | 90 | 120 | 180 | 270 | 360 | 15 m* | |
A) Prevalence (% of cases) | |||||||||
Current study | |||||||||
Alb 400 mg | 100.0 | 100.0 | 100.0 | 94.7 | - | 94.7 | 84.2 | 73.7 | - |
Alb 400 mg + DEC 6 mg/kg bodyweight | 100.0 | 100.0 | 100.0 | 100.0 | - | 94.4 | 83.3 | 72.2 | - |
Previous studies (single dose) Alb 400 mg | |||||||||
Ismail et al., (1998)† | - | - | - | - | - | - | - | - | 91.7 |
Addiss et al., (1997) | - | - | - | - | 76.0 | - | - | - | - |
Beach et al., (1999) | - | - | - | - | 85.0 | - | - | - | - |
Dunyo et al., (2000) | - | - | - | - | - | - | - | 91.9 | - |
Previous studies (single dose) Alb 400 mg + DEC 6 mg/kg | |||||||||
Ismail et al., (1998)† | - | - | - | - | - | - | - | - | 72.7 |
B) Changes in parasite density (geometric mean) as compared to pre-therapy level | |||||||||
Current study | |||||||||
Alb 400 mg | 100.0 | 85.9 | 59.5 | 34.9 | - | 25.8 | 14.5 | 5.3 | - |
Alb 400 mg + DEC 6 mg/kg bodyweight | 100.0 | 54.9 | 39.1 | 22.0 | - | 19.0 | 12.3 | 4.6 | - |
Previous studies (single dose) Alb 400 mg | |||||||||
Ismail et al., (1998)† | - | - | - | - | - | - | - | - | 9.8 |
Addiss et al., (1997) | - | - | - | - | 63.8 | - | - | - | - |
Beach et al., (1999) | - | - | - | - | - | - | - | - | - |
Dunyo et al., (2000) | - | - | - | - | - | - | - | 31.7 | - |
Previous studies (single dose) Alb 400 mg + DEC 6 mg/kg | |||||||||
Ismail et al., (1998)† | - | - | - | - | - | - | - | - | 1.3 |